GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -77.76 Billion KRW | -103.85% |
| 2022 | -38.15 Billion KRW | -139.16% |
| 2021 | -15.95 Billion KRW | 14.46% |
| 2020 | -18.64 Billion KRW | -144.78% |
| 2019 | -7.61 Billion KRW | 35.97% |
| 2018 | -11.89 Billion KRW | 49.86% |
| 2017 | -23.72 Billion KRW | -52.12% |
| 2016 | -15.59 Billion KRW | -1203.36% |
| 2015 | 1.41 Billion KRW | 121.78% |
| 2014 | -6.49 Billion KRW | 22.37% |
| 2013 | -8.36 Billion KRW | 5.91% |
| 2012 | -8.88 Billion KRW | -80.04% |
| 2011 | -4.93 Billion KRW | 34.97% |
| 2010 | -7.59 Billion KRW | 9.78% |
| 2009 | -8.41 Billion KRW | -43.88% |
| 2008 | -5.84 Billion KRW | -101.51% |
| 2007 | -2.9 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.48 Billion KRW | 76.18% |
| 2024 Q2 | -12.8 Billion KRW | -35.07% |
| 2023 FY | -77.76 Billion KRW | -103.85% |
| 2023 Q1 | -13.21 Billion KRW | 9.82% |
| 2023 Q2 | -13.19 Billion KRW | 0.11% |
| 2023 Q3 | -11.55 Billion KRW | 12.42% |
| 2023 Q4 | -39.8 Billion KRW | -244.38% |
| 2022 Q2 | -10.97 Billion KRW | -137.43% |
| 2022 Q3 | -7.9 Billion KRW | 27.97% |
| 2022 FY | -38.15 Billion KRW | -139.16% |
| 2022 Q4 | -14.65 Billion KRW | -85.35% |
| 2022 Q1 | -4.62 Billion KRW | -97.84% |
| 2021 Q1 | -1.82 Billion KRW | 80.83% |
| 2021 FY | -15.95 Billion KRW | 14.46% |
| 2021 Q4 | -2.33 Billion KRW | 57.53% |
| 2021 Q2 | -6.28 Billion KRW | -243.4% |
| 2021 Q3 | -5.5 Billion KRW | 12.46% |
| 2020 Q4 | -9.54 Billion KRW | -185.11% |
| 2020 FY | -18.64 Billion KRW | -144.78% |
| 2020 Q3 | -3.34 Billion KRW | 7.84% |
| 2020 Q2 | -3.63 Billion KRW | -71.12% |
| 2020 Q1 | -2.12 Billion KRW | 23.81% |
| 2019 FY | -7.61 Billion KRW | 35.97% |
| 2019 Q1 | -459.66 Million KRW | 84.11% |
| 2019 Q2 | -3.97 Billion KRW | -764.81% |
| 2019 Q3 | -397.46 Million KRW | 90.0% |
| 2019 Q4 | -2.78 Billion KRW | -601.01% |
| 2018 Q3 | -2.9 Billion KRW | 5.89% |
| 2018 Q4 | -2.89 Billion KRW | 0.44% |
| 2018 Q2 | -3.08 Billion KRW | -2.47% |
| 2018 Q1 | -3.01 Billion KRW | 58.11% |
| 2018 FY | -11.89 Billion KRW | 49.86% |
| 2017 Q1 | -5.01 Billion KRW | -10.7% |
| 2017 Q3 | -3.57 Billion KRW | 54.94% |
| 2017 Q4 | -7.19 Billion KRW | -100.98% |
| 2017 FY | -23.72 Billion KRW | -52.12% |
| 2017 Q2 | -7.94 Billion KRW | -58.34% |
| 2016 Q4 | -4.53 Billion KRW | 3.15% |
| 2016 FY | -15.59 Billion KRW | -1203.36% |
| 2016 Q3 | -4.67 Billion KRW | 9.61% |
| 2016 Q2 | -5.17 Billion KRW | -326.51% |
| 2016 Q1 | -1.21 Billion KRW | -230.61% |
| 2015 Q1 | -830.72 Million KRW | 78.31% |
| 2015 Q3 | 3.52 Billion KRW | 484.35% |
| 2015 FY | 1.41 Billion KRW | 121.78% |
| 2015 Q4 | -367.05 Million KRW | -110.4% |
| 2015 Q2 | -918.43 Million KRW | -10.56% |
| 2014 Q4 | -3.83 Billion KRW | -292.06% |
| 2014 FY | -6.49 Billion KRW | 22.37% |
| 2014 Q3 | -977 Million KRW | 27.0% |
| 2014 Q2 | -1.33 Billion KRW | -286.84% |
| 2014 Q1 | -345.95 Million KRW | 33.25% |
| 2013 Q2 | -2.81 Billion KRW | 12.93% |
| 2013 Q1 | -3.23 Billion KRW | -26.06% |
| 2013 Q3 | -1.79 Billion KRW | 36.46% |
| 2013 Q4 | -518.24 Million KRW | 71.06% |
| 2013 FY | -8.36 Billion KRW | 5.91% |
| 2012 FY | -8.88 Billion KRW | -80.04% |
| 2012 Q2 | -2.48 Billion KRW | -144.76% |
| 2012 Q3 | -1.33 Billion KRW | 46.18% |
| 2012 Q4 | -2.56 Billion KRW | -91.66% |
| 2012 Q1 | -1.01 Billion KRW | 0.0% |
| 2011 Q3 | -123.43 Million KRW | 89.29% |
| 2011 FY | -4.93 Billion KRW | 34.97% |
| 2011 Q2 | -1.15 Billion KRW | -198.19% |
| 2011 Q1 | -386.57 Million KRW | 0.0% |
| 2011 Q4 | - KRW | 100.0% |
| 2010 FY | -7.59 Billion KRW | 9.78% |
| 2010 Q3 | -2.17 Billion KRW | -276.78% |
| 2010 Q2 | -577.06 Million KRW | 26.39% |
| 2010 Q1 | -783.94 Million KRW | 0.0% |
| 2010 Q4 | - KRW | 100.0% |
| 2009 Q2 | -4.53 Billion KRW | -967.41% |
| 2009 Q3 | -2.27 Billion KRW | 49.95% |
| 2009 Q4 | - KRW | 100.0% |
| 2009 FY | -8.41 Billion KRW | -43.88% |
| 2009 Q1 | -424.95 Million KRW | 86.59% |
| 2008 Q3 | -446.81 Million KRW | 66.05% |
| 2008 Q4 | -3.16 Billion KRW | -609.35% |
| 2008 FY | -5.84 Billion KRW | -101.51% |
| 2008 Q2 | -1.31 Billion KRW | -43.54% |
| 2008 Q1 | -916.91 Million KRW | 29.06% |
| 2007 Q4 | -1.29 Billion KRW | -65.66% |
| 2007 Q2 | -1.36 Billion KRW | -354.83% |
| 2007 Q3 | -780.25 Million KRW | 42.87% |
| 2007 Q1 | 535.99 Million KRW | 0.0% |
| 2007 FY | -2.9 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 12.87 Billion KRW | 704.209% |
| Green Cross Holdings Corporation | -54.13 Billion KRW | -43.652% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | -192.012% |
| Pharmicell Co., Ltd. | 3.57 Billion KRW | 2273.516% |
| Green Cross Corporation | -26.63 Billion KRW | -192.012% |
| Celltrion, Inc. | 535.64 Billion KRW | 114.518% |
| Samsung Biologics Co.,Ltd. | 857.69 Billion KRW | 109.067% |
| SK bioscience Co.,Ltd. | 22.31 Billion KRW | 448.459% |
| SK Biopharmaceuticals Co., Ltd. | -32.88 Billion KRW | -136.5% |
| Prestige BioPharma Limited | -32.92 Billion KRW | -136.225% |